Pulse Biosciences grants options to major holder
PULSE BIOSCIENCES, INC. director and 10% owner Robert W. Duggan received two stock option grants as equity compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PULSE BIOSCIENCES, INC. director and 10% owner Robert W. Duggan received two stock option grants as equity compensation. He was awarded options for 12,495 shares and 30,000 shares of common stock at an exercise price of $26.89 per share, expiring on June 11, 2036. The options vest over one year, with one grant vesting in equal monthly installments starting on July 11, 2026 and the other vesting in equal quarterly installments starting on September 5, 2026, subject to his continued service.
Insider Trade Summary
Grant/Award: 42,495 shares
Grant/Award
2 txns
Insider
DUGGAN ROBERT W
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) | 12,495 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 42,495 contracts (Direct)
Footnotes (2)
- F1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
- F2. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Key Figures
Option grant 1 size: 12,495 options
Option grant 2 size: 30,000 options
Exercise price: $26.89 per share
+4 more
7 metrics
Option grant 1 size
12,495 options
Stock Option (right to buy) underlying common stock
Option grant 2 size
30,000 options
Stock Option (right to buy) underlying common stock
Exercise price
$26.89 per share
Conversion or exercise price for both option grants
Total underlying shares
42,495 shares
Sum of underlying common stock for both grants
Expiration date
June 11, 2036
Expiration for both stock option grants
Monthly vesting start
July 11, 2026
First installment for one option grant
Quarterly vesting start
September 5, 2026
First installment for the other option grant
Key Terms
Stock Option (right to buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 26.8900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to the option will vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PLSE reporting person Robert W. Duggan report?
Robert W. Duggan reported receiving two stock option grants in Pulse Biosciences. The awards cover 12,495 and 30,000 underlying common shares and were granted at an exercise price of $26.89 per share as part of his equity compensation.
Are Robert W. Duggan’s PLSE transactions open-market buys or option grants?
The transactions are option grants, not open-market share purchases. Both are coded as grant or award acquisitions, giving rights to buy 12,495 and 30,000 PLSE shares at a fixed exercise price of $26.89 per share.
How do the new Pulse Biosciences options granted to Robert W. Duggan vest?
The options vest over one year, subject to continued service. One grant vests in equal monthly installments starting July 11, 2026, while the other vests in equal quarterly installments starting September 5, 2026, increasing his exercisable position over time.
What is the expiration date of Robert W. Duggan’s new PLSE stock options?
Both stock option grants expire on June 11, 2036. After that date, any unexercised options become worthless, so the effective life of these compensation awards is about 10 years from the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates